Skip to main content
Erschienen in: Obesity Surgery 6/2016

04.09.2015 | Original Contributions

Circulating SIRT1 Increases After Intragastric Balloon Fat Loss in Obese Patients

verfasst von: Stefania Mariani, Daniela Fiore, Agnese Persichetti, Sabrina Basciani, Carla Lubrano, Eleonora Poggiogalle, Alfredo Genco, Lorenzo Maria Donini, Lucio Gnessi

Erschienen in: Obesity Surgery | Ausgabe 6/2016

Einloggen, um Zugang zu erhalten

Abstract

Background

Sirtuins (SIRTs), ubiquitous deacetylases, are main regulators of energy homeostasis and metabolism. SIRT1 has a positive impact on obesity, diabetes mellitus, liver steatosis, and other metabolic disorders. Lean subjects have higher expression of SIRT1 in the adipose tissue compared to obese. However, it is not known whether weight loss associates with changes in blood SIRT1. We evaluated the effect of weight loss on circulating SIRT1, metabolic parameters, and body composition.

Methods

Thirty-two obese subjects were studied before and 6 months after BioEnterics® Intragastric Balloon (BIB®) [22 patients, BMI 41.82 ± 6.28 kg/m2] or hypocaloric diet [10 patients, BMI 38.95 ± 6.90 kg/m2]. Plasma SIRT1, body composition, measures of metabolic syndrome (waist circumference, fasting plasma glucose, blood pressure, HDL cholesterol, triglycerides), and inflammation markers (ESR, CRP, fibrinogen) were recorded.

Results

SIRT1 levels showed a significant increase, together with a significant reduction of BMI, excess body weight, and total fat mass either after BIB or diet intervention. The percent excess body weight loss was 33.73 ± 19.06 and 22.08 ± 11.62 % after BIB and diet, respectively, a trend toward a metabolic and inflammatory amelioration was observed with both treatments. Negative correlation between SIRT1 and % fat mass (BIB, ρ = −0.537, p = 0.017; diet, ρ = −0.638, p = 0.047) was also seen.

Conclusions

The reduction of fat mass associates with increased plasma SIRT1 indicating that, besides tissue levels, circulating SIRT1 is stimulated by a negative caloric balance. The rise of plasma SIRT1 may represent a parameter associating with fat loss rather than weight lowering regardless of the weight reduction system method used.
Literatur
2.
Zurück zum Zitat Herranz D, Munoz-Martin M, Canamero M, et al. Sirt1 improves healthy ageing and protects from metabolic syndrome-associated cancer. Nat Commun. 2010;1:3–17.CrossRefPubMedPubMedCentral Herranz D, Munoz-Martin M, Canamero M, et al. Sirt1 improves healthy ageing and protects from metabolic syndrome-associated cancer. Nat Commun. 2010;1:3–17.CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Saunders LR, Verdin E. Sirtuins: critical regulators at the crossroads between cancer and aging. Oncogene. 2007;26(37):5489–504.CrossRefPubMed Saunders LR, Verdin E. Sirtuins: critical regulators at the crossroads between cancer and aging. Oncogene. 2007;26(37):5489–504.CrossRefPubMed
4.
Zurück zum Zitat Mariani S, Fiore D, Basciani S, Persichetti A, Contini S, Lubrano C, et al. Plasma levels of SIRT1 asso ciate with non-alcoholic fatty liver disease in obese patients. Endocrine. 2015;49(3):711–6. Mariani S, Fiore D, Basciani S, Persichetti A, Contini S, Lubrano C, et al. Plasma levels of SIRT1 asso ciate with non-alcoholic fatty liver disease in obese patients. Endocrine. 2015;49(3):711–6.
5.
Zurück zum Zitat Xu F, Gao Z, Zhang J, et al. Lack of SIRT1 (mammalian sirtuin 1) activity leads to liver steatosis in the SIRT1+/− mice: a role of lipid mobilization and inflammation. Endocrinology. 2010;151(6):2504–14.CrossRefPubMedPubMedCentral Xu F, Gao Z, Zhang J, et al. Lack of SIRT1 (mammalian sirtuin 1) activity leads to liver steatosis in the SIRT1+/− mice: a role of lipid mobilization and inflammation. Endocrinology. 2010;151(6):2504–14.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Purushotham A, Schug TT, Xu Q, et al. Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell Metab. 2009;9(4):327–38.CrossRefPubMedPubMedCentral Purushotham A, Schug TT, Xu Q, et al. Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell Metab. 2009;9(4):327–38.CrossRefPubMedPubMedCentral
9.
10.
Zurück zum Zitat Xu F, Burk D, Gao Z, et al. Angiogenic deficiency and adipose tissue dysfunction are associated with macrophage malfunction in SIRT1-/- mice. Endocrinology. 2012;153(4):1706–16.CrossRefPubMedPubMedCentral Xu F, Burk D, Gao Z, et al. Angiogenic deficiency and adipose tissue dysfunction are associated with macrophage malfunction in SIRT1-/- mice. Endocrinology. 2012;153(4):1706–16.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Picard F, Kurtev M, Chung N, et al. Machado De Oliveira R, et al. Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature. 2004;429(6993):771–6.CrossRefPubMedPubMedCentral Picard F, Kurtev M, Chung N, et al. Machado De Oliveira R, et al. Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature. 2004;429(6993):771–6.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Kitada M, Kume S, Takeda-Watanabe A, et al. Calorie restriction in overweight males ameliorates obesity-related metabolic alterations and cellular adaptations through anti-aging effects, possibly including AMPK and SIRT1 activation. Biochim Biophys Acta. 2013;1830(10):4820–7.CrossRefPubMed Kitada M, Kume S, Takeda-Watanabe A, et al. Calorie restriction in overweight males ameliorates obesity-related metabolic alterations and cellular adaptations through anti-aging effects, possibly including AMPK and SIRT1 activation. Biochim Biophys Acta. 2013;1830(10):4820–7.CrossRefPubMed
13.
Zurück zum Zitat Genco A, Maselli R, Frangella F, Cipriano M, Forestieri P, Delle Piane D, et al. Intragastric balloon for obesity treatment: results of a multicentric evaluation for balloons left in place for more than 6 months. Surg Endosc. 2015;29:2339–43. Genco A, Maselli R, Frangella F, Cipriano M, Forestieri P, Delle Piane D, et al. Intragastric balloon for obesity treatment: results of a multicentric evaluation for balloons left in place for more than 6 months. Surg Endosc. 2015;29:2339–43.
14.
Zurück zum Zitat Conference NIH. Gastrointestinal surgery for severe obesity. Consensus development conference panel. Ann Intern Med. 1991;115(12):956–61.CrossRef Conference NIH. Gastrointestinal surgery for severe obesity. Consensus development conference panel. Ann Intern Med. 1991;115(12):956–61.CrossRef
15.
Zurück zum Zitat Genco A, Cipriano M, Bacci V, et al. BioEnterics Intragastric Balloon (BIB): a short-term, double-blind, randomised, controlled, crossover study on weight reduction in morbidly obese patients. Int J Obes (Lond). 2006;30(1):129–33.CrossRef Genco A, Cipriano M, Bacci V, et al. BioEnterics Intragastric Balloon (BIB): a short-term, double-blind, randomised, controlled, crossover study on weight reduction in morbidly obese patients. Int J Obes (Lond). 2006;30(1):129–33.CrossRef
16.
Zurück zum Zitat Mariani S, Fiore D, Barbaro G, et al. Association of epicardial fat thickness with the severity of obstructive sleep apnea in obese patients. Int J Cardiol. 2013;167(5):2244–9.CrossRefPubMed Mariani S, Fiore D, Barbaro G, et al. Association of epicardial fat thickness with the severity of obstructive sleep apnea in obese patients. Int J Cardiol. 2013;167(5):2244–9.CrossRefPubMed
17.
Zurück zum Zitat Lubrano C, Saponara M, Barbaro G, et al. Relationships between body fat distribution, epicardial fat and obstructive sleep apnea in obese patients with and without metabolic syndrome. PLoS One. 2012;7(10), e47059.CrossRefPubMedPubMedCentral Lubrano C, Saponara M, Barbaro G, et al. Relationships between body fat distribution, epicardial fat and obstructive sleep apnea in obese patients with and without metabolic syndrome. PLoS One. 2012;7(10), e47059.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Cummins TD, Holden CR, Sansbury BE, et al. Metabolic remodeling of white adipose tissue in obesity. Am J Physiol Endocrinol Metab. 2014;307(3):262–77.CrossRef Cummins TD, Holden CR, Sansbury BE, et al. Metabolic remodeling of white adipose tissue in obesity. Am J Physiol Endocrinol Metab. 2014;307(3):262–77.CrossRef
19.
Zurück zum Zitat Quiñones M, Al-Massadi O, Fernø J, et al. Cross-talk between SIRT1 and endocrine factors: effects on energy homeostasis. Mol Cell Endocrinol. 2014;397(1-2):42–50.CrossRefPubMed Quiñones M, Al-Massadi O, Fernø J, et al. Cross-talk between SIRT1 and endocrine factors: effects on energy homeostasis. Mol Cell Endocrinol. 2014;397(1-2):42–50.CrossRefPubMed
20.
Zurück zum Zitat Pfluger PT, Herranz D, Velasco-Miguel S, et al. Sirt1 protects against high-fat diet-induced metabolic damage. Proc Natl Acad Sci U S A. 2008;105(28):9793–8.CrossRefPubMedPubMedCentral Pfluger PT, Herranz D, Velasco-Miguel S, et al. Sirt1 protects against high-fat diet-induced metabolic damage. Proc Natl Acad Sci U S A. 2008;105(28):9793–8.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Pang W, Wang Y, Wei N, et al. Sirt1 inhibits akt2-mediated porcine adipogenesis potentially by direct protein-protein interaction. PLoS One. 2013;8(8), e71576.CrossRefPubMedPubMedCentral Pang W, Wang Y, Wei N, et al. Sirt1 inhibits akt2-mediated porcine adipogenesis potentially by direct protein-protein interaction. PLoS One. 2013;8(8), e71576.CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Song YS, Lee SK, Jang YJ, et al. Association between low SIRT1 expression in visceral and subcutaneous adipose tissues and metabolic abnormalities in women with obesity and type 2 diabetes. Diabetes Res Clin Pract. 2013;101(3):341–8.CrossRefPubMed Song YS, Lee SK, Jang YJ, et al. Association between low SIRT1 expression in visceral and subcutaneous adipose tissues and metabolic abnormalities in women with obesity and type 2 diabetes. Diabetes Res Clin Pract. 2013;101(3):341–8.CrossRefPubMed
23.
Zurück zum Zitat Pedersen SB, Olholm J, Paulsen SK, et al. Low Sirt1 expression, which is upregulated by fasting, in human adipose tissue from obese women. Int J Obes (Lond). 2008;32(8):1250–5.CrossRef Pedersen SB, Olholm J, Paulsen SK, et al. Low Sirt1 expression, which is upregulated by fasting, in human adipose tissue from obese women. Int J Obes (Lond). 2008;32(8):1250–5.CrossRef
24.
Zurück zum Zitat Moschen AR, Wieser V, Gerner RR, et al. Adipose tissue and liver expression of SIRT1, 3, and 6 increase after extensive weight loss in morbid obesity. J Hepatol. 2013;59(6):1315–22.CrossRefPubMed Moschen AR, Wieser V, Gerner RR, et al. Adipose tissue and liver expression of SIRT1, 3, and 6 increase after extensive weight loss in morbid obesity. J Hepatol. 2013;59(6):1315–22.CrossRefPubMed
26.
Zurück zum Zitat Baksi A, Kraydashenko O, Zalevkaya A, et al. A phase II, randomized, placebo-controlled, double-blind, multi-dose study of SRT2104, a SIRT1 activator, in subjects with type 2 diabetes. Br J Clin Pharmacol. 2014;78(1):69–77.CrossRefPubMedPubMedCentral Baksi A, Kraydashenko O, Zalevkaya A, et al. A phase II, randomized, placebo-controlled, double-blind, multi-dose study of SRT2104, a SIRT1 activator, in subjects with type 2 diabetes. Br J Clin Pharmacol. 2014;78(1):69–77.CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Aasen G, Fagertun H, Halse J. Regional fat mass by DXA: high leg fat mass attenuates the relative risk of insulin resistance and dyslipidaemia in obese but not in overweight postmenopausal women. Scand J Clin Lab Invest. 2008;68(3):204–11.CrossRefPubMed Aasen G, Fagertun H, Halse J. Regional fat mass by DXA: high leg fat mass attenuates the relative risk of insulin resistance and dyslipidaemia in obese but not in overweight postmenopausal women. Scand J Clin Lab Invest. 2008;68(3):204–11.CrossRefPubMed
Metadaten
Titel
Circulating SIRT1 Increases After Intragastric Balloon Fat Loss in Obese Patients
verfasst von
Stefania Mariani
Daniela Fiore
Agnese Persichetti
Sabrina Basciani
Carla Lubrano
Eleonora Poggiogalle
Alfredo Genco
Lorenzo Maria Donini
Lucio Gnessi
Publikationsdatum
04.09.2015
Verlag
Springer US
Erschienen in
Obesity Surgery / Ausgabe 6/2016
Print ISSN: 0960-8923
Elektronische ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-015-1859-4

Weitere Artikel der Ausgabe 6/2016

Obesity Surgery 6/2016 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.